

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM791574

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Endo Pharmaceuticals Inc.		02/22/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Teikoku Pharma USA, Inc.		
Street Address:	1718 Ringwood Ave.		
City:	San Jose		
State/Country:	CALIFORNIA		
Postal Code:	95131		
Entity Type:	Corporation: CALIFORNIA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	2853072	LIDODERM	
Registration Number:	2870973	LIDODERM	
Registration Number:	1597110	LIDODERM	
CORRESPONDENCE DATA			
Fax Number:	4153939887		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	415-954-0200		
Email:	ip-squiretm@squirepb.com		
Correspondent Name:	Phillip R. Zender		
Address Line 1:	Squire Patton Boggs (US) LLP		
Address Line 2:	475 Sansome Street, Suite 1600		
Address Line 4:	San Francisco, CALIFORNIA 94111		
ATTORNEY DOCKET NUMBER:	103444.00030		
NAME OF SUBMITTER:	Phillip R. Zender		
SIGNATURE:	/philip r. zender/		
DATE SIGNED:	03/03/2023		
Total Attachments: 1			
source=Lidoderm Trademark Assignment (Signed February 22 2023)#page1.tif			

CH \$90.00 2853072

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT is made and entered into as of February 22, 2023 (the "Effective Date") by and between Endo Pharmaceuticals Inc., Debtor-in-Possession, a Delaware corporation with its principal place of business at 1400 Atwater Drive, Malvern, Pennsylvania 19355 ("Assignor"), and Teikoku Pharma USA, Inc., California corporation with its principal place of business at 1718 Ringwood Avenue, San Jose, California 95131 ("Assignee").

WHEREAS, on August 16, 2022, Assignor, together with its affiliates, filed a voluntary petition for relief under chapter 11 of Title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"), which case is pending as Case No. 22-22549 (Jointly Administered) (the "Bankruptcy Cases");

WHEREAS, on November 11, 2022, the Bankruptcy Court entered the *Order (I) Authorizing and Approving Procedures for (A) the Use, Sale, Transfer, or Abandonment of De Minimis Assets Free and Clear of Liens, Claims, Interests and Encumbrances Without Further Order of the Court and (B) the Acquisition of De Minimis Assets; (II) Authorizing the Payment of Related Fees and Expenses; and (III) Granting Related Relief* [Docket No. 700] (the "Sale Order") pursuant to which the Assignor obtained authority to, without further order of the Bankruptcy Court, transfer the Lidoderm Trademarks (as defined below) free and clear of liens, claims, encumbrances and interests pursuant to section 363(f) of the Bankruptcy Code;


WHEREAS, Assignor is the owner of all right, title and interest in and to the LIDODERM trademark (with and without design elements), including without limitation the following U.S. trademark registrations: U.S. Registration Numbers 2853072, 2870973, and 1597110 (collectively, the "Lidoderm Trademarks"), together with the goodwill of the business symbolized thereby in connection with the goods on which the Lidoderm Trademarks are used by Assignor;


WHEREAS, Assignee wishes to acquire the Lidoderm Trademarks and the associated trademark registrations therefor and Assignor wishes to transfer, as permitted by the Sale Order, the Lidoderm Trademarks to Assignee;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby assigns to Assignee, and its successors and assigns, all rights, title and interest in and to the Lidoderm Trademarks, together with the goodwill of the business symbolized by the Lidoderm Trademarks, and the associated trademark registrations therefor, and including the right to sue for and receive all damages from past infringements arising prior to the Effective Date, the same to be held and enjoyed by Assignee, its successors, assigns, and legal representatives.

Assignor
ENDO PHARMACEUTICALS INC.

Assignee
TEIKOKU PHARMA USA, INC.

By: 
Name: Jenny P. Johnson
Title: Vice President, Intellectual Property
Date: February 22, 2023

DocuSigned by:
By: 
Name: Ichiro Mori
Title: President & CEO
Date: 3/1/2023